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Neurobiology of Disease
SIRT1 Modulates Aggregation and Toxicity through
Deacetylation of the Androgen Receptor in Cell Models
of SBMA
Heather L. Montie,1 Richard G. Pestell,2 and Diane E. Merry1
Departments of 1Biochemistry and Molecular Biology, and 2Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Posttranslational protein modifications can play a major role in disease pathogenesis; phosphorylation, sumoylation, and acetylation
modulate the toxicity of a variety of proteotoxic proteins. The androgen receptor (AR) is substantiallymodified, in response to hormone
binding, byphosphorylation, sumoylation, andacetylation; thesemodificationsmight thus contribute toDHT-dependent polyglutamine
(polyQ)-expandedARproteotoxicity in spinal and bulbarmuscular atrophy (SBMA). SIRT1, a nuclear protein and deacetylase of the AR,
is neuroprotective in many neurodegenerative disease models. Our studies reveal that SIRT1 also offers protection against polyQ-
expanded AR by deacetylating the AR at lysines 630/632/633. This finding suggested that nuclear AR acetylation plays a role in the
aberrant metabolism and toxicity of polyQ-expanded AR. Subsequent studies revealed that the polyQ-expanded AR is hyperacetylated
and that pharmacologic reduction of acetylation reducesmutantARaggregation.Moreover, geneticmutation to inhibit polyQ-expanded
ARacetylation of lysines 630/632/633 substantially decreased its aggregation and completely abrogated its toxicity in cell lines andmotor
neurons. Our studies also reveal one means by which the AR acetylation state likely modifies polyQ-expanded AR metabolism and
toxicity, through its effect on DHT-dependent AR stabilization. Overall, our findings reveal a neuroprotective function of SIRT1 that
operates through its deacetylation of polyQ-expanded AR and highlight the potential of both SIRT1 and AR acetylation as powerful
therapeutic targets in SBMA.
Introduction
The sirtuins are a family of NAD-dependent deacetylases that are
linked to the regulation of lifespan and protection against pro-
teotoxicity (for review, see Haigis and Sinclair, 2010; Huber and
Superti-Furga, 2011). SIRT1, in particular, plays a protective role
in several models of neurodegeneration, includingWallerian de-
generation (Araki et al., 2004), Alzheimer’s disease (Qin et al.,
2006; Kim et al., 2007; Min et al., 2010), and ALS (Kim et al.,
2007). The mechanistic basis for SIRT1 neuroprotection may
involve its role as a deacetylase of several nonhistone proteins,
including PGC1 (Rodgers et al., 2005), HSF1 (Westerheide et
al., 2009), and Atg5, Atg7, and Atg8 (Lee et al., 2008).
Protein acetylation and other posttranslational modifications
play an important role in the dynamic regulation of protein func-
tion, trafficking, and turnover and can thus directly modify the
toxicity of disease-causing proteins. Acetylation can play a role in
neurodegeneration by directly modifying proteotoxic proteins.
Degradation of tau is inhibited by its acetylation and enhanced by
SIRT1-dependent deacetylation (Min et al., 2010), consistent
with the protective effect of sirtuins inmodels of AD and tauopa-
thies (for review, see Haigis and Sinclair, 2010). Lysine acetyla-
tion also regulates the degradation of two polyQ-expanded
proteins, huntingtin and ataxin-7, by promoting (Jeong et al.,
2009) or inhibiting (Mookerjee et al., 2009), respectively, the
targeting of these proteins to the autophagic pathway. The fact
that one posttranslational modification can elicit distinct effects
on different proteins containing the same geneticmutation high-
lights both the significance of specific protein context and the role
of normal protein metabolism in polyQ expansion disease.
The androgen receptor (AR), in which polyQ expansion
causes the neurodegenerative neuromuscular disease spinal and
bulbar muscular atrophy (SBMA) (La Spada et al., 1991), is a
nuclear receptor that has been well studied for its roles in endo-
crine dysfunction and prostate cancer (for review, seeGao, 2010).
Investigations into its normal function and metabolism have re-
vealed important aspects of diseasemechanism in SBMA, includ-
ing hormone binding (Katsuno et al., 2002; Takeyama et al., 2002;
Chevalier-Larsen et al., 2004), nuclear localization (Takeyama
et al., 2002; Montie et al., 2009; Nedelsky et al., 2010), AF2-
coactivator interactions (Nedelsky et al., 2010), and the AR
amino-carboxyl interaction (Orr et al., 2010). The AR undergoes
manyposttranslationalmodifications, both hormone-dependent
and hormone-independent, throughout its normal metabolism.
These modifications, which include phosphorylation, sumoylation,
Received Aug. 2, 2011; revised Sept. 22, 2011; accepted Oct. 8, 2011.
Author contributions: H.M. and D.E.M. designed research; H.M. performed research; R.P.P. contributed unpub-
lished reagents/analytic tools; H.M. and D.E.M. analyzed data; H.M., R.P.P., and D.E.M. wrote the paper.
This workwas supported by NIH Grants R01 NS047381, R01 NS32214 (D.E.M.), and DK07705 (H.L.M.) and by the
Kennedy’s Disease Association (H.L.M). We thank Yuhong Liu, M.S., for technical assistance with dissociated spinal
cord cultures and Michael Powell for thoughtful discussions.
The authors declare no competing financial interests.
Correspondence should be addressed to Dr. Diane E. Merry, Department of Biochemistry and Molecular Biology,
Thomas JeffersonUniversity, 228 Bluemle Life Sciences Building, 223 S. 10th Street, Philadelphia, PA 19107. E-mail:
diane.merry@jefferson.edu.
DOI:10.1523/JNEUROSCI.3958-11.2011
Copyright © 2011 the authors 0270-6474/11/3117425-12$15.00/0
The Journal of Neuroscience, November 30, 2011 • 31(48):17425–17436 • 17425
ubiquitylation, and acetylation, impact aspects of AR metabolism,
including trafficking, protein interactions, transcriptional activa-
tion, and degradation.
In our studies here to determine the role of SIRT1 in SBMA
pathogenesis, we found that SIRT1 is strongly neuroprotective in
cell models of SBMA and that the function of SIRT1 to deacety-
late the AR is a critical component of its neuroprotection. More-
over, we found that polyQ-expanded AR is hyperacetylated and
that acetylation modulates its nuclear aggregation and toxicity.
One mechanism by which acetylation may impact the aggrega-
tion and toxicity of polyQ-expandedAR is through the regulation
of AR degradation. Our studies presented here highlight the ther-
apeutic potential of SIRT1 and its direct role of modulating AR
acetylation in SBMA.
Materials andMethods
Creation of stable SIRT1 and SIRT1(H363Y) Tet-On AR112Q and AR10Q
PC12 cell lines. Stable transfection of SIRT1-myc-his and SIRT1(H363Y)-
myc-his (pcDNA3.1 plasmid backbone) into Tet-On AR112Q or AR10Q
PC12 cells was performed using a calcium phosphate protocol. Cotransfec-
tion with pBABE-puro plasmid was used to confer resistance for the selec-
tionof colonies. Stable transformantswere selectedwith2g/mlpuromycin
(Invitrogen). Single colonies were isolated and expanded and screened for
SIRT1-myc-his protein expression by Western blot analysis using SIRT1
antibody (Millipore).
Creation ofARacetylation-mutantTet-OnPC12 cells.pTRE-AR(10-CAG)
was used as a template for site-directed mutagenesis (Quick Change II XL,
Stratagene). Nucleic acids that encode Lys-630 were mutated to encode an
acetylation-null argininewithin the protein.NruI/BstBI digestswere used to
clone thismutation intopTRE-NLSX3-AR(111-CAG) (Montie et al., 2009),
yielding pTRE-NLSX3-AR-K630A(111-CAG). pTRE-AR(10-CAG) was
used as a template for site-directed mutagenesis of nucleic acids en-
coding Lys-630, Lys-632, and Lys-633 to acetylation-null arginine (R)
and acetylation-mimic threonine (T) or glutamine (Q). The acetylation
mutations were cloned into the pTRE-NLSX3-AR(111-CAG) plasmid with
NruI and BstBI, yielding NLSX3-AR-K630,632,633R(111-CAG), NLSX3-
AR-K630,632,633T(111-CAG), and NLSX3-AR-K630,632,633Q(111-
CAG). All constructs were sequenced to verify mutation and CAG length.
Stable transfection of Tet-On PC12 cells (Clontech) with NLSX3-AR
constructs and a plasmid conferring hygromycin resistance (pTK-
hygromycin) was performed using a calcium phosphate protocol. Stable
transformants were selected with 200g/ml hygromycin. Single colonies
were isolated and expanded and screened for doxycycline-inducible AR
protein expression by slot blot and Western analysis using an antibody
against AR (AR-H280; Santa Cruz Biotechnology). AR expression in the
various mutant cell lines was adjusted using doxycycline to achieve pro-
tein levels equivalent to that in NLSX3-AR110Q-expressing PC12 cells.
Genomic DNA was extracted from each clone to verify mutation and
CAG length via sequence analysis. Cells were maintained in normal
growthmedia [DMEMwith 10%heat-inactivated horse serum, 5%heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin, 200g/ml hygromycin (Invitrogen), and 100g/ml G418
(Mediatech)] at 37°C, 10% CO2.
Creation of adeno-associated viruses. pcDNA3.1-SIRT1-myc-his and
pcDNA3.1-SIRT1(H363Y)-myc-hisweredigestedwithBamHIandPmeI to
remove SIRT1-myc-his and SIRT1(H363Y)-myc-his cDNA and the ends
were filled in with Klenow. The cis-adeno-associated viral (AAV) plasmid
(serotype 1), with CMV enhancer and chicken -actin promoter, was di-
gestedwith EcoRV and EcoRI and the ends were blunted with Klenow.
Ligations were performed to produce cis-AAV-SIRT1-myc-his and
cis-AAV-SIRT1(H363Y)-myc-his. To create adeno-associated viruses
expressing AR, pTRE plasmids containing NLSX3-AR(111-CAG),
NLSX3-AR-K630,632,633R(111-CAG) (R3), or NLSX3-AR-K630,
632,633Q(111-CAG) (Q3) cDNAs were digested with NheI and BamHI to
remove the AR-encoding fragment and the ends filled in with Klenow. The
AR-encoding fragment was ligated into the cis-AAV plasmid that was di-
gested as described above. Mutations and CAG repeat lengths were con-
firmed by sequence analysis.
All AAV cis-plasmids described above were co-transfected into
HEK393T cells with trans (H21) and adenovirus helper (pF6) plasmids
using a calcium phosphate protocol. After 5 d in culture, cells were lysed
by repeated freeze/thaw in Opti-MEM (Invitrogen) to release AAV from
cells, and lysates were centrifuged and filtered to remove cellular debris.
The appropriate volume of cell lysate to achieve the highest, equiva-
lent infection of motor neurons within dissociated spinal cord cultures
was determined by serial dilution infections of wild-type (nontrans-
genic) cultures and subsequent immunostaining forAR (AR-318), c-myc
(Santa Cruz Biotechnology), and neurofilament-heavy chain (SMI32).
siRNA reduction of SIRT1. Stable Tet-On PC12 cells were transfected
with SIRT1 siRNA by electroporation, using an Amaxa nucleoporator
(Mirus), following the specified protocol for PC12 cells. Fifty picomoles
of either nontargeting siRNA (ON-TARGETplus Nontargeting siRNA
#1; Dharmacon) or SIRT1 siRNA (AAGATGAAGTTGACCTCCTCA)
(Rodgers et al., 2005) (Qiagen) were electroporated into 4 million
AR112Q-PC12cells.Cellswereplatedandtreated24h laterwithdoxycycline
and10nMDHTfor anadditional 48h.Cellswereharvestedandevaluatedby
Western blot for SIRT1 protein and by immunofluorescence for AR aggre-
gation. All experiments were performed in triplicate at least three times.
Student’s t test was used to determine statistical significance.
Treatment of inducible PC12 cell lines for AR aggregation analysis. Stable
Tet-On PC12 cell lines were treated with doxycycline to express equivalent
levels of NLSX3-AR110Q (K3), NLSX3-AR(K630A)110Q (K630A),
NLSX3-AR(K630,632,633R)110Q (R3), NLSX3-AR(K630,632,633T)110Q
(T3), andNLSX3-AR(K630,632,633Q)110Q (Q3) for 48 hwith EtOHor 10
nMDHT in charcoal-stripped serum-containing cell culture media. Immu-
nofluorescence was performed to detect AR (AR-H280) and cells were visu-
alized with a Leica microscope equipped with epifluorescence. Three
hundred cells fromrandomfieldswere counted from three replicatewells by
an observer blinded to the experimental condition, and the percentage of
cells with nuclear inclusions of ARwas calculated and graphed. Cells treated
in parallel were harvested for biochemical analysis. All experiments were
performed in triplicate at least three times. Statistical significance was deter-
mined with ANOVA and Tukey post hoc analysis (SigmaStat).
PC12 cell toxicity assay. Stable Tet-On PC12 cell lines were treated with
doxycycline to express equivalent levels of AR, in the presence and ab-
sence of 10 nM DHT, for 12 d. At the end of the treatment regimen, cells
were harvested and stained with Trypan blue to reveal dead cells. Two
hundred cells were counted by an observer blinded to the experimental
condition and the percentage of Trypan blue-positive (dead) cells was
determined. All experiments were performed in triplicate at least three
times. Statistical significance was determined by ANOVA and Tukey post
hoc analysis (SigmaStat).
AR stabilization by DHT. Stable Tet-On PC12 cell lines were treated
with doxycycline to express equivalent levels of AR for 48 h in charcoal-
stripped serum-containing media. Cells were then washed three times
with PBS to remove doxycycline and inhibit new AR protein translation.
At this time triplicate samples from each cell line were harvested to serve
as theDHT-untreated sample. The remaining wells of cells received fresh
media containing 10 nM DHT for an additional 36 h, at which time these
samples were harvested and AR levels determined by Western analysis.
Student’s t test was used to determine statistical significance.
Immunofluorescence. PC12 cells and dissociated spinal cord cultures
were fixed with 4% paraformaldehyde for 15 min, washed in PBS, per-
meabilizedwith 0.3%TritonX-100 for 15min, blocked in 2%goat serum
(Jackson ImmunoResearch) for 20 min, and incubated for 60 min in
primary antibody diluted in 1.5% goat serum. Cells were washed in PBS
and incubated for 30min with secondary antibodies (FITC-, Texas Red-,
or Alexa Fluor 350-conjugated; Jackson ImmunoResearch and Invitro-
gen), washed in PBS, incubated for 10 min with Hoechst (2 g/ml),
washed in PBS, and mounted with Vectashield (Vector Laboratories).
Fluorescence was visualized with a Leica (Leica Microsystems) micro-
scope; images were captured with a Leica camera and compiled with IP
Lab software (BD Biosciences). Antibodies used include AR-H280 (1:
100; Santa Cruz Biotechnology), AR-318 (1:50; Vector Laboratories),
SMI32 (1:1000; Sternberger Monoclonal), anti-His-tag (1:200; Milli-
pore), anti-His-tag (1:50; Cell Signaling Technology), and anti-c-Myc
(1:100; Santa Cruz Biotechnology).
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Western blot analysis. Protein extracts were prepared by lysing cells
with Triton-DOC lysis buffer (1% sodiumdeoxycholate and 0.5%Triton
X-100 in PBS with protease inhibitors) or lysis buffer for acetyl-lysine
immunoprecipitation (20 mM Tris, pH 7.5, 150 nM NaCl, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
-glycerophosphate, 1 mM sodium orthovanadate, 1g/ml Leupeptin, 1
mM PMSF, and 5 mM sodium butyrate). All lysates were sonicated three
times for 10 s using a Branson cup sonifier and a DC protein assay
(Bio-Rad) was performed to determine protein concentration. Lysates
were electrophoresed by SDS-PAGE and transferred to 0.45 m PVDF
(Immobilon-P).Western hybridization was performed using the follow-
ing antibodies diluted in 5% nonfat milk: AR-H280 (1:1000; Santa Cruz
Biotechnology), GAPDH (1:100,000; Fitzgerald), tubulin (1:2000;
Sigma), SIRT1 (1:2000; Millipore), acetyl-lysine (1:1000; Cell Signaling
Technology), and HMGB1 (1:500; Novus). Detection was performed
with ECL [Pierce (Thermo Fisher)].
Nuclear/Cytoplasmic fractionation of PC12 cells. Stable Tet-On PC12
cell lines were treated with doxycycline to express equivalent levels of
AR10Q or AR112Q in the presence of 10 nMDHT for 48 h. Ten thousand
cells from each conditionwere lysed inNP-40 buffer (10mMTris, pH7.4,
10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 5 mM sodium butyrate and
protease inhibitors) and fractionated by centrifugation. Twenty percent
of the nuclear and cytoplasmic fractions were removed and electropho-
resed by SDS-PAGE, andWestern analysis was
performed (AR-H280, Santa Cruz Biotechnol-
ogy) to determine AR localization. The integrity
of the fractions was determined using antibodies
specific to nuclear (HMGB1, Novus) and cyto-
plasmic (GAPDH, Fitzgerald) fractions. The
remainder of the fractions underwent immuno-
precipitation of acetyl-lysine as outlined below.
Immunoprecipitation of acetyl-lysine. Cells
were washed with PBS and lysed with acetyl-
lysine buffer or NP40 buffer (described above).
Lysates were sonicated three times for 10 s us-
ing a Branson cup sonifier. A DC protein assay
(Bio-Rad)was performed to determine protein
concentration. Two-hundred and fifty or five-
hundred micrograms of protein (or in the case
of nuclear/cytoplasmic fractions, 80% of the
fraction) from each cell line was precleared
with 20 l of protein G Dynabeads (Invitro-
gen) in a total volume of 250l and rotated for
45 min at room temperature. Dynabeads were
removed from lysates (withDynalmagnet) and
2.5 l of anti-acetyl-lysine antibody (Cell Sig-
naling Technology) was added to the samples
and incubated at 4°Covernight.Dynabeads (20
l) were added to the lysates and rotated at
room temperature for 45min. Dynabeads were
then removed from the lysates andwashed four
times with lysis buffer, then proteins were
eluted by boiling in 2 Laemmli buffer for 5
min. Samples were evaluated by SDS-PAGE
and Western blot for AR (AR-H280) as out-
lined above. Following evaluation of AR detec-
tion, membranes were stripped and reprobed
with acetyl-lysine antibody to determine the
efficiency of the immunoprecipitation. To de-
termine relative levels of acetylated AR, densi-
tometric values of AR following acetyl-lysine
IP were divided by the AR value from the total
lysate for each sample. Such analysis was per-
formed on triplicate samples and a Student’s
t test was performed to determine statistical
significance.
Dissociated spinal cord cultures. Dissociated
spinal cord cultures were established according
to Roy et al. (1998) and as described byMontie
et al. (2009). Transgenic mouse genotyping
was performed from a tail biopsy as described by Chevalier-Larsen et al.
(2004); male and female embryos were not distinguished. Transgenic
AR112Q and nontransgenic spinal cords were pooled separately, plated
for culture, and incubated for 3 weeks in media conditioned by embry-
onic 13.5 d nontransgenic brain glial cells [MEM, 35mMNaHCO3, 0.5%
dextrose, 1% N3] supplemented with 10 nM 2.5 S NGF. After 3 weeks,
AR112Q cultures were treated with AAV-EGFP, AAV-SIRT1, or AAV-
SIRT1(H363Y). Non-transgenic cultures were treated with AAV-NLSX3-
AR111CAG, AAV-NLSX3-AR111CAG (R3), AAV-NLSX3-AR111CAG
(Q3), AAV-SIRT1, or AAV-EGFP for 5 d. At this time, replicate wells were
treated with 10MDHT for 6 h and subsequently analyzed by immunoflu-
orescence todetermine thepercentage infectivity of eachviral construct.The
remaining cultureswere treatedwith EtOHor 10MDHT for an additional
7 d. Three wells of cells from each treatment group were immuno-
stained as described above. Motor neurons were identified by analysis of
neurofilament-heavy chain (SMI32antibody) andmorphology.Motorneu-
rons from 10 random fields from each of three separate wells were counted
using 20,000 magnification by an observer blinded to the experimental
condition. Statistical significance was determined by ANOVA and post hoc
Tukey test (SigmaStat). All procedures involving mice were performed fol-
lowing theguidelinesof the InstitutionalAnimalCareandUseCommitteeof
Thomas Jefferson University.
Figure 1. SIRT1 abrogatesmutant AR aggregation and toxicity in amanner dependent upon its deacetylase activity. PC12 cells
expressing AR112Q were stably transfected with either SIRT1 or deacetylase-deficient SIRT1(H363Y). A, Stable overexpression of
SIRT1 in AR112Q-expressing PC12 cells resulted in a significant reduction in the number of cells containing nuclear inclusions,
comparedwith control, following treatmentwith 10 nM DHT for 48 h, while deacetylase-deficient SIRT1(H363Y) increased nuclear
inclusions. ANOVAwith post hoc Tukey test was performed to determine statistical significance. *p 0.01 B, Western analysis of
AR in cells treated in parallel with those inA reveals a substantial decrease in SDS-insoluble AR112Q upon overexpression of SIRT1,
and an increase in high molecular weight species upon overexpression of SIRT1(H363Y). C, Cells were treated for 12 d with either
10 nM DHT or EtOH. Two hundred cells were counted from triplicate wells for each treatment and the percentage of Trypan
blue-positive cellswas graphed. SIRT1 rescuedAR112Q-expressing PC12 cells fromDHT-dependent death,while SIRT1(H363Y) did
not. Also note that SIRT1(H363Y) enhanced DHT-dependent death. ANOVA with post hoc Tukey test was performed to determine
statistical significance. *p 0.05.
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Results
SIRT1 abrogates polyQ-expanded AR aggregation and
toxicity
SIRT1 is neuroprotective in numerous neurodegenerative dis-
eases (for review, see Haigis and Sinclair, 2010). We wished to
investigate the ability of SIRT1 to modulate aggregation and tox-
icity in cell models of SBMA. PC12 cells that inducibly express
polyglutamine (polyQ)-expanded AR (AR112Q) form polyQ
length- and DHT-dependent nuclear inclusions of proteolyzed
polyQ-expanded AR (Walcott andMerry, 2002), similar to those
found in patient tissue (Li et al., 1998), and die in response to
DHT (Montie et al., 2009). Stable overexpression of SIRT1 in this
cellmodel resulted in a substantial decrease in the number of cells
with nuclear inclusions (Fig. 1A), reduced the amount of SDS-
insoluble AR112Q observed by Western analysis (Fig. 1B), and
rescued cells from DHT-dependent death (Fig. 1C). This ability
of SIRT1 to reduce AR112Q aggregation and to inhibit toxicity
was dependent upon its deacetylase domain, as expression of
SIRT1 bearing a mutation previously shown to eliminate its
deacetylase activity [SIRT1(H363Y)] (Tanny et al., 1999) failed to
reduce AR112Q aggregation and toxicity (Fig. 1). Moreover, ex-
pression of deacetylase-deficient SIRT1(H363Y) substantially in-
creased the number of cells with nuclear inclusions (Fig. 1A) and
enhanced cell death (Fig. 1C). Overexpression of SIRT1 or of
SIRT1(H363Y) had no effect on the nuclear localization of ex-
panded AR following 30 min, 1, 2, or 48 h of DHT treatment,
assessed by immunostaining of AR protein (data not shown).
Given the effect of SIRT1 overexpression on polyQ-expanded
AR aggregation and toxicity, we wished to determine the role of
endogenous SIRT1 in these events. We used siRNA to knock
down SIRT1 (Rodgers et al., 2005) in the PC12 cell model of
SBMA, described above. We achieved a 77% knockdown of
SIRT1 protein using a single siRNA (Fig. 2A). This reduction in
SIRT1 expression resulted in a significant increase in polyQ-
expanded AR aggregation (Fig. 2B), revealing a role for endoge-
nous SIRT1 in the prevention of polyQ-expanded aggregation.
SIRT1 protects motor neurons expressing polyQ-expanded
AR fromDHT-dependent death
Having demonstrated a beneficial role of SIRT1 in abrogating the
aberrant aggregation and toxicity of polyQ-expandedAR inPC12
cells, we wished to determine whether SIRT1 would also have a
therapeutic benefit in the disease-relevant cell type, motor neurons.
Thus, we initiated mixed spinal cord cultures containing motor
neurons from transgenic mice expressing polyQ-expanded AR,
as previously described (Mojsilovic-Petrovic et al., 2009; Montie
et al., 2009; Orr et al., 2010). Motor neurons expressing AR112Q
in these cultures die in response to DHT (Montie et al., 2009).
Treatment of AR112Q-expressing cultures with AAV-EGFP also
resulted inDHT-dependent death (Fig. 3). However, overexpres-
sion of SIRT1 abrogatedDHT-dependent death ofmotor neurons
in amanner dependent upon its deacetylase activity, as deacetylase-
deficient SIRT1(H363Y) did not rescue expanded AR-expressing
motor neurons from DHT-dependent death (Fig. 3). These data
further substantiate a neuroprotective role of SIRT1 in SBMA and
highlight its potential as a promising candidate for therapeutic
development.
SIRT1 reduces AR acetylation at lysines 630, 632, and 633
We demonstrated that the deacetylase activity of SIRT1 is essen-
tial for its role in ameliorating polyQ-expanded AR aggregation
and toxicity (Figs. 1, 3). Of the many known SIRT1 substrates,
one of note is theAR itself (Fu et al., 2006). SIRT1 has been shown
to specifically deacetylate lysines 630, 632, and 633 within an AR
with normal polyglutamine length (Fu et al., 2006). Thus, we
evaluated the effect of SIRT1 overexpression on the acetylation of
polyQ-expanded AR. We found that SIRT1 overexpression de-
creased AR112Q acetylation in a manner dependent upon its
deacetylase activity (Fig. 4A,B).
We next sought to determine whether the effect of SIRT1 on
polyQ-expanded AR acetylation is due to its ability to deacetylate
lysines 630, 632, and 633. The three lysines within the AR that are
acetylated in response to hormone are clustered in the KLKK
motif located in the hinge region at positions 630/632/633 (Fu et
al., 2000). This sequence is part of a bipartite nuclear localization
signal (Simental et al., 1991; Zhou et al., 1994) and mutation of
these lysines within normal Q-length AR reduces hormone-
dependent nuclear AR transit (Zhou et al., 1994; Thomas et al.,
2004; Shiota et al., 2010). To circumvent the complication of
reduced nuclear AR localization, we introduced a heterologous
nuclear localization signal [cloned in triplicate (NLSX3)], fused
to the AR N terminus, as previously described (Montie et al.,
2009). We used Tet-On PC12 cells expressing AR110Q with ei-
ther intact lysines 630, 632, and 633 (K3) or acetylation-null mu-
tation at amino acids 630, 632, and 633 (R3), resulting in the
inability of this AR protein to be acetylated at lysines 630, 632,
633, as previously shown (Fu et al., 2006). We also created two
cell lines with an additional modification by stably overexpress-
ing SIRT1 in AR110Q-K3- and AR110Q-R3-expressing PC12
cells. Evaluation of AR acetylation following DHT treatment re-
vealed a substantial decrease in acetylated AR110Q-K3 upon
Figure 2. Reduction of SIRT1 in cells expressing polyglutamine-expanded AR increases nu-
clear inclusions. PC12 cells were treated with siRNA against SIRT1 or nontargeting siRNA.
Twenty-four hours later cells were treated with doxycycline to induce AR112Q expression and
10 nM DHT. A, After 48 h, cells were harvested and expression of SIRT1 and AR (AR-H280) was
evaluated by Western analysis. Seventy-seven percent knockdown of SIRT1 was achieved.
GAPDHwas used as a loading control.B, Cells treated as inAwere fixed and immunostained for
AR (AR-H280), and 300 cells from each of three wells per treatment were counted and the
number of cells with AR nuclear inclusions was determined. Reduction of SIRT1 significantly
increased the number of cellswith nuclear inclusions of AR112Q. Student’s t testwas performed
to determine statistical significance. *p 0.01.
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SIRT1 overexpression, but no effect of SIRT1 overexpression
on the already low levels of AR acetylation observed for
AR110Q(R3) (Fig. 5). These results indicate that lysines 630/632/
633, previously shown to be deacetylated by SIRT1 (Fu et al.,
2006), are critical for SIRT1 to decrease the acetylation of
polyglutamine-expanded AR.
The ability of SIRT1 to protect motor neurons expressing
polyQ-expanded AR from death is dependent upon intact AR
lysines 630, 632, 633
Given the role of AR lysines 630, 632, and 633 in the reduction of
AR acetylation by SIRT1, we questioned whether the neuropro-
tective effect of SIRT1 in SBMA cell models depends on its ability
to deacetylate these three lysines.We used dissociated spinal cord
cultures to determine whether SIRT1 would protect motor neu-
rons expressing polyQ-expanded AR with a mutation at lysines
630, 632, and 633 that bothmimics acetylation and prevents their
deacetylation (K630Q/K632Q/K633Q; Q3) (Fu et al., 2003).
SIRT1 overexpression in motor neurons expressing polyQ-
expanded AR with intact lysines (AR111Q-K3) rescued them
from DHT-dependent death (Fig. 6). However, SIRT1 failed to
protect motor neurons expressing AR111Q-Q3 (acetylation-
mimic) from DHT-dependent AR toxicity (Fig. 6). These data
indicate that lysines 630, 632, and 633 are necessary for the
Figure 3. SIRT1 protects motor neurons expressing polyglutamine-expanded AR from DHT-dependent death. Dissociated spinal cord cultures were initiated from transgenic mouse embryos
expressing AR112Q. SIRT1, deacetylase deficient SIRT1 (SIRT1(H363Y); both tagged with myc-his) or EGFP were overexpressed using AAV infection. Five days after infection, cultures were treated
with DHT or EtOH for an additional 7 d andmotor neuron number was determined. SIRT1 expression was assayed using an anti-myc antibody. A, Motor neurons from 10 random fields of cells were
countedunder 20,000magnification from triplicatewells for each treatment and the averagenumber ofmotor neuronswas determined. SIRT1protectedAR112Q-expressingmotor neurons from
DHT-dependent death, while SIRT1(H363Y) did not. B, Images represent motor neurons treated with DHT as described in A. NF-H, Unphosphorylated neurofilament-heavy chain. Percentage
infectivity of motor neurons with AAV: 92% EGFP (control), 88% SIRT1, and 94% SIRT1(H363Y). ANOVA with post hoc Tukey test was performed to determine statistical significance. *p 0.01.
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neuroprotective effect of SIRT1 on polyQ-expanded AR toxicity
in motor neurons.
Polyglutamine-expanded AR is hyperacetylated
Our finding that SIRT1 decreases the acetylation of lysine 630,
632, and 633 within polyQ-expanded AR and that these three
lysines are critical for the neuroprotective effect of SIRT1 in mo-
tor neurons expressing polyQ-expanded AR led us to question
whether polyQ-expanded AR is aberrantly acetylated. We com-
pared the acetylation status of polyQ-expanded AR to that of
normal Q-length AR by using Tet-on PC12 cells that express
normal Q-length (AR10Q) or expanded Q-length AR (AR112Q)
(Fig. 7). We found that AR112Q, in the presence of hormone, is
acetylated to a greater extent than AR10Q (2.4-fold greater, p
0.05).Moreover, consistent with the importance of nuclear local-
ization of the expanded AR for disease manifestation, we ob-
served, using fractionated cell extracts, the exclusive localization
of hyperacetylated AR112Q within the nucleus (Fig. 7B).
Pharmacologic reduction of acetylation decreases
nuclear inclusions
To investigatewhether the enhanced acetylation ofAR112Qplays
a role in its aberrant aggregation, we used pharmacologic means
to reduce AR112Q acetylation and evaluated the effect on AR
aggregation. We observed a significant reduction in the num-
ber of cells with nuclear inclusions when AR112Q acetylation
was reduced with anacardic acid (36% reduction, p 0.01), an
inhibitor of the histone acetyltransferases CBP/p300 and
PCAF (Fig. 8).
Figure 5. Lysines 630, 632, and 633 within the AR are required for SIRT1 to decrease
polyglutamine-expanded AR acetylation. PC12 cells expressing polyQ-expanded AR110Q with
an exogenous nuclear localization signal in triplicate (NLSX3) were used for these studies. PC12
cells expressing AR110Q or AR110Qwith lysines 630, 632, and 633mutated to acetylation-null
arginine (AR110Q-R3) in the presence and absence of stable overexpression of SIRT1 were
treatedwith10nMDHT for 48h.Acetyl-lysinewas immunoprecipitated fromprotein lysates and
AR levels determined by Western analysis (AR-H280). Overexpression of SIRT1 reduced the
levels of acetylatedAR110Q,while ithadnoeffecton levelsofacetylatedAR110Q-R3.Notethat levels
of acetylated AR111Q-R3were reduced comparedwith those of AR110Q. Equivalent levels of acetyl-
lysinewere immunoprecipitated from each sample (data not shown).Western analysis of total pro-
tein lysates revealed equivalent levels of ARbetween cell lines.
Figure 4. SIRT1 reduces acetylation of polyQ-expanded AR. A, Cells were treatedwith 10 nM
DHT or EtOH for 48 h. Immunoprecipitation (IP) of acetyl-lysine and immunoblotting (IB) for AR
(AR-H280) revealed a substantial reduction in AR112Q acetylation when SIRT1, but not SIRT1
(H363Y), was overexpressed. Western analysis revealed equivalent levels of AR between cell
lines. B, Relative densitometric values of AR following acetyl-lysine IP and Western analysis of
AR in AR112Q-expressing cells and in AR112Q-expressing cells that coexpress either SIRT1 or
SIRT1 (H363Y). The level of acetylated AR in AR112Q cellswas set as 100. A significant reduction
in AR112Q acetylationwas observed in the presence of SIRT1. Student’s t test was performed to
determine statistical significance. *p 0.05.
Figure 6. The neuroprotective role of SIRT1 in motor neurons expressing polyQ-expanded
AR is dependent upon AR lysines 630, 632, and 633. Dissociated spinal cord cultures were
initiated fromnontransgenic embryonicmice.AAVsweremade toexpress EGFP, SIRT1-myc-his,
AR111Q, or acetylation-mimic AR111Q-Q3 [both forms of AR contain an exogenous nuclear
localization signal in triplicate (NLSX3) at theN terminus]. After 5d, thepercentage infectivity of
motor neurons with AR, EGFP, and SIRT1 was determined by immunofluorescence. The rest of
the cultures were then treated with either EtOH or DHT for an additional 7 d. Immunofluores-
cence analysis was performed to reveal motor neurons (with antibody SMI32) and AR (AR-318)
andHoechst 33258wasused to stainnuclei.Motorneuronswere counted from10 randomfields
of cells under 20,000magnification from triplicate wells for each treatment. The number of
viable motor neurons expressing AR is represented in the graph. DHT treatment significantly
reduced the number of motor neurons expressing AR111Q/EGFP, as well as those expressing
AR111Q-Q3/EGFP. SIRT1 overexpression in motor neurons expressing AR111Q (lysine intact)
rescued these motor neurons from DHT-dependent death, while SIRT1 did not protect motor
neurons expressing AR111Q-Q3 (acetylation-mimic). ANOVAwith post hoc Tukey test was per-
formed to determine statistical significance. *p 0.001.
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Genetic inhibition of polyQ-expanded AR acetylation
ameliorates its aggregation and toxicity
We next used a genetic approach to directly evaluate the role of
polyQ-expanded AR acetylation in its aggregation and toxicity
and generated multiple Tet-inducible PC12 cell lines expressing
various acetylation-mutant forms of AR. For these studies, we
used AR constructs with a heterologous nuclear localization sig-
nal fused to the N terminus of the AR, due to the potential effect
of mutation of K630/K632/K633 on AR nuclear localization. The
presence of the heterologous nuclear localization signal resulted
in nuclear localization of all AR proteins, even in the absence of
hormone (data not shown).
A single acetylation-null mutation (K630A) in polyQ-
expanded AR (AR110Q) resulted in both fewer cells with nuclear
inclusions (Fig. 9A) and resistance to DHT-dependent death
(Fig. 9B). Moreover, the acetylation-null mutation of all three
lysines (K630,632,633R) (R3) resulted in an even more substan-
tial reduction in AR110Q nuclear inclusions (Fig. 9A) and also
abrogated DHT-dependent death (Fig. 9B). Biochemical analysis
revealed a reduction in SDS-insoluble species of AR-K630A-
110Q and the near elimination of SDS-insoluble species of
AR110Q-R3 (Fig. 9C). Conversely, acetylationmimic (threonine;
T3) -expressing cells displayed an increase in the number of cells
with AR nuclear inclusions and enhanced toxicity (Fig. 9A,B).
Expression of expanded AR with an alternative acetylation-
mimic (glutamine;Q3)mutation resulted in the sameARnuclear
inclusion load and toxicity as cells expressing lysine-intact
AR110Q (Fig. 9A,B). Biochemical analysis revealed increased
SDS-insoluble acetylation-mimic AR110Q (T3 and Q3) com-
paredwith lysine-intact AR110QuponDHT treatment (Fig. 9C).
Normal Q-length acetylationmutant AR-expressing cells did not
form nuclear inclusions (data not shown) nor did they die in
response to DHT treatment (Fig. 9B). These data indicate that
lysines 630, 632, and 633, which are acetylated in response to
DHT (Fu et al., 2003), are critical to the aberrant aggregation and
toxicity of polyQ-expanded AR.
Acetylation-null polyQ-expanded AR does not induce
DHT-dependent death of motor neurons
We next sought to determine whether AR acetylation is required
for the toxic effects of polyQ-expandedAR in the disease-relevant
Figure 7. Nuclear polyglutamine-expanded AR is hyperacetylated compared with normal
glutamine-length AR. AR10Q and AR112Q-expressing PC12 cells were treated with 10 nM DHT
for 48 h. A, Acetylation of AR was evaluated by immunoprecipitation (IP) of acetyl-lysine from
cell lysates and subsequentWestern analysis. A representativeWestern blot shows that a larger
proportion of AR112Q is acetylated compared with AR10Q, and that acetylated AR112Q is ob-
served in an SDS-insoluble form in the well and stacking layer of the gel. Reprobing of the
membrane revealed equivalent acetyl-lysine immunoprecipitated from AR10Q and AR112Q
lysates. Western analysis of total lysate reveals equivalent AR levels. GAPDH was used as a
loading control for total lysates.B, Nuclear and cytoplasmic fractionsof cell lysateswereused for
immunoprecipitation (IP) of acetyl-lysine, and the immunoprecipitates were electrophoresed
by SDS-PAGE and immunoblotted (IB) for AR (ARH280). Nuclear, but not cytoplasmic, AR10Q
and AR112Q were immunoprecipitated with acetyl-lysine antibody. The nuclear/cytoplasmic
fractionswere verified by running a portion of the fractions on an SDS-page gel and probing the
membrane for AR, nuclear (HMGB1), and cytoplasmic (GAPDH)markers. Note that the signal in
the upper-left portion of the ARH280-probed membrane represents nonspecific background
signal. There is only a faint signal of AR10Q in the nuclear fraction at 110 kDa. C, Cytoplasmic
fraction; N, nuclear fraction.
Figure 8. Pharmacologic reduction of polyglutamine-expanded AR reduces nuclear in-
clusions. AR112Q-expressing PC12 cells were treated in triplicate for 48 h with 10 nM DHT
in the presence and absence of 30M anacardic acid (inhibitor of CBP/p300 and PCAF). A,
Immunoprecipitation of acetyl-lysine and subsequent Western analysis for AR revealed
that AA treatment reduced acetylation of AR112Q. Shown here is a representative
Western blot. B, AR112Q-expressing cells treated in parallel were fixed and immuno-
stained for AR. Five-hundred cells were counted from each of three wells and the percent-
age of cells with nuclear inclusions graphed. Anacardic acid reduced the number of cells
with nuclear inclusions. Student’s t test was performed to determine statistical signifi-
cance. *p 0.01.
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cell type, motor neurons. For these studies, we initiated mixed
spinal cord cultures from nontransgenic, wild-type mice and
infected motor neurons with AAVs that express either NLSX3-
AR111Q (K3; lysine intact) or NLSX3-AR111Q (R3; acetylation-
null) to determine whether prevention of AR acetylation at
lysines 630, 632, and 633 would protect motor neurons from
DHT-dependent death. For these experiments, a heterologous
nuclear localization signal was fused to the N terminus of the acety-
lationmutant AR to ensure nuclear localization of polyQ-expanded
AR (Fig. 10A). Motor neurons expressing AR111Q died in re-
sponse to DHT, whereas motor neurons expressing equivalent
levels (Fig. 10B) of acetylation-null AR111Q (AR111Q-R3) re-
mained viable (Fig. 10C). These results further validate a role for
lysines 630, 632, and 633 within the AR in DHT-dependent,
polyQ-expanded AR motor neuron toxicity.
Acetylation of poly-Q expanded AR enhances stabilization of
the protein by DHT
To begin to understand the mechanism by which acetylation of
polyQ-expanded AR is involved in its aggregation and toxicity,
we assessed DHT-dependent stabilization of the AR with muta-
tions at lysines 630, 632, and 633. Unlike other nuclear receptors
(for review, see (Stanisic´ et al., 2010), the AR is stabilized upon
hormone binding (Wright et al., 1981; Kemppainen et al., 1992).
As acetylation of the AR occurs in response to hormone binding,
we questioned whether the acetylation state of the polyQ-
expanded AR contributes to its stabilization. We evaluated the
effect ofmutation of lysines 630, 632, and 633 on the stabilization
of AR110Q in the presence of DHT. As shown in Figure 9C, all
acetylationmutant forms of AR110Qwere stabilized byDHT. To
more precisely analyze the effect of AR acetylation on its stabili-
zation in response to hormone binding, we used conditions of
minimal aggregation and inhibition of new AR synthesis. We
took advantage of the inducible nature of AR in Tet-On PC12
cells to manipulate the production of AR and treated Tet-On
PC12 cells with doxycycline to express AR110Qwith either intact
lysines (K3), or with acetylation-null (K630A and R3) or
acetylation-mimic (T3 andQ3)mutations.We then inhibitedAR
production by washing out doxycycline and treated cells with
DHT to compare AR levels before and after DHT treatment.
Under these conditions, a significant stabilization of AR110Q
protein was revealed upon DHT treatment, as expected (Fig. 11).
However,mutation of lysine 630 to an acetylation-null alanine or
mutation of lysines 630, 632, and 633 to acetylation-null argi-
nines reduced the stabilization of AR by DHT (Fig. 11). There
was, however, a significant stabilization of AR when these lysines
Figure 9. Genetic inhibition of mutant AR acetylation ameliorates polyQ-expanded AR aggregation and toxicity. PC12 cells expressing polyQ-expanded AR110Q with an exogenous
nuclear localization signal in triplicate (NLSX3) at the N terminus were used for these studies. Cells expressing a single acetylation-null mutation (AR-K630A–110Q), a triple acetylation-
null mutant (AR-R3–110Q), or triple acetylation-mimic mutant (AR-T3–110Q or AR-Q3–110Q) were treated with 10 nM DHT or EtOH for 48 h. A, Cells were immunostained and the
percentage of cells (300 cells from triplicate wells) containing nuclear inclusions was graphed. A substantial reduction in the number of cells with nuclear inclusions was observed upon
expression of acetylation-null (K630A; R3) expanded AR, while an increase (T3) or a similar inclusion load (Q3) was observed upon expression of acetylation-mimic expanded AR. ANOVA
with post hoc Tukey test was performed to determine statistical significance. *p 0.05 B. Cells were treated for 12 d and evaluated for cell death. Two hundred cells were counted from
triplicate wells for each treatment. Normal AR110Q- and acetylation-mimic AR-expressing cells died in response to DHT, while acetylation-null AR-expressing cells remained viable.
AR35Q-expressing cells did not form inclusions or die in response to DHT. ANOVA with post hoc Tukey test was performed to determine statistical significance. *p 0.01 C, Western
analysis of AR (AR-H280) revealed equivalent levels of AR between all cell lines. GAPDH served as a loading control. A longer development of the AR immunoblot revealed a substantial
reduction in SDS-insoluble polyQ-expanded AR in cells expressing acetylation-null AR, while there was an increase in SDS-insoluble highmolecular weight species of AR in cells expressing
acetylation-mimic AR.
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were mutated to either of the acetylation-mimic amino acids
threonine (T3) or glutamine (Q3). In fact, the DHT-induced
T3-mutant AR was substantially more stabilized than was lysine-
intact AR110Q (Fig. 11). This finding may explain the higher
propensity of this mutant AR to aggregate and induce toxicity in
PC12 cells (Fig. 9A,B). We thus conclude that acetylation of
polyQ-expanded AR enhances its stabilization in the presence of
DHT. These data suggest that one mechanism by which the acet-
ylation state of polyQ-expanded AR impacts its aggregation and
toxicity is by regulating the steady-state levels of the mutant pro-
tein in the presence of DHT.
Discussion
The understanding of a role for protein posttranslational modi-
fications in the pathogenesis of several neurodegenerative dis-
eases has fueled research into the validation of suchmodifications
as “druggable” therapeutic targets. Such transient protein modi-
fication has the potential to alter protein metabolism and func-
Figure 10. Acetylation-null polyQ-expanded AR does not induce DHT-dependent death of motor neurons. Dissociated spinal cord cultures were initiated from nontransgenic embryonic mice.
AAVsweremade to expressAR111Qor acetylation-null AR111Q-R3with anexogenousnuclear localization signal in triplicate (NLSX3) at theN terminus. The cultureswere infectedwith these viruses
to achieve an equal number ofmotor neurons expressing AR. After 5 d, cultures were treatedwith either EtOH or DHT for an additional 7 d.A, Image represents immunofluorescence of DHT-treated
cultures that were noninfected or infected with virus expressing AR111Q or AR111Q-R3. Percentage infectivity of motor neurons with AAV 78% AR111Q, 82% AR111Q-R3. B, Protein lysates
harvested from DHT-treated cultures and analyzed by Western blotting using AR-H280 and GAPDH as a loading control. Similar levels of AR111Q and AR111Q-R3 were observed. C, The number of
motor neurons expressing ARwas graphed following 7 d of EtOH or DHT treatment. Immunofluorescence analysis was performed to reveal motor neurons (with antibody SMI32) and AR (AR-318);
Hoechst 33258 was used to stain nuclei. Motor neurons were counted from 10 random fields of cells under 20,000 magnification from triplicate wells for each treatment. DHT treatment
significantly reduced the number of motor neurons expressing AR111Q, while DHT had no effect on the number of viable motor neurons expressing acetylation-null AR111Q-R3. ANOVA was
performed with post hoc Tukey test to determine significance. *p 0.005.
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tion and, in the case of disease-causing proteins, can significantly
impact proteotoxicity.
The acetylation of polyQ-expandedAR represents a candidate
posttranslational AR modification for evaluation due to its de-
pendence on AR hormone binding, a critical feature of disease in
SBMA (Katsuno et al., 2002; Takeyama et al., 2002; Chevalier-
Larsen et al., 2004). Sites of acetylation on the AR are clustered in
the KLKKmotif located in the hinge region at positions 630/632/
633 (Fu et al., 2000). Regulation of AR acetylation occurs through
the combined activities of the nuclear type A acetyltransferases
CBP/p300, PCAF, Tip60 (Fu et al., 2000, 2003; Gaughan et al.,
2002; Gong et al., 2006) and the deacetylases HDAC1 (Gaughan
et al., 2002) and SIRT1 (Fu et al., 2006).
SIRT1, while better known for its effects on longevity and
calorie restriction-induced cellular protection, gained recent at-
tention for its protective role in neurodegenerative diseases (for
review, see Haigis and Sinclair, 2010; Huber and Superti-Furga,
2011). Additional studies have revealed the ability of SIRT1 to
deacetylate a host of proteins, including several involved in neu-
rodegenerative disorders. We thus reasoned that SIRT1 might
also be neuroprotective in SBMA.
We found that SIRT1 reduced DHT-dependent nuclear
polyQ-expanded AR aggregation and toxicity in cell models of
SBMA. Moreover, the deacetylase activity of SIRT1 was crucial
for this effect, as deacetylase-deficient SIRT1(H363Y) did not
prevent toxicity or decrease AR aggregation, but rather increased
these disease features, perhaps by preventing the binding of en-
dogenous SIRT1 to the mutant AR. Consistent with this inter-
pretation is the result of our studies in which SIRT1 protein
knockdown (Fig. 2), or inhibitionwith Sirtinol (data not shown),
increased expanded AR aggregation. Our finding that the
deacetylase activity of SIRT1 was critical to its ability to reduce
polyQ-expanded AR aggregation complements our finding of
decreased AR aggregation in the presence of the acetyltransferase
inhibitor anacardic acid and suggested that SIRT1 may function
to decrease polyQ-AR aggregation and toxicity directly, through
its deacetylation of the mutant AR. However, as SIRT1 has broad
neuroprotective effects on various cellular pathways (Bouras et
al., 2005; Rodgers et al., 2005; Lee et al., 2008; Westerheide et al.,
2009), we thought it also possible that its effects on AR toxicity
might be indirect. To our surprise, the neuroprotective effect of
SIRT1 on motor neurons was completely dependent upon this
direct ability of SIRT1 to deacetylate AR.
The effect of SIRT1 on bothAR acetylation and its aggregation and
toxicity suggested that AR acetylation at K630/K632/K633 plays a cen-
tral role intheaggregationandtoxicityofpolyQ-expandedAR.Infact,a
role for these lysines in AR cytoplasmic/nuclear trafficking and folding
homeostasis was previously informed by Lieberman’s group (Thomas
et al., 2004), whichmotivated us to evaluate the role of nuclear polyQ-
expanded AR acetylation in disease. Confirmation of our hypothesis
that AR acetylation is a modifier of expanded AR proteotoxicity was
providedbygenetic studies inwhichtheacetylation-mimicsubstitution
of threonine for lysine enhanced the aggregation and toxicity of polyQ-
expanded AR. Moreover, mutation of K630/K632/K633 to an
acetylation-null amino acid (arginine) almost entirely prevented ex-
pandedARaggregationandcompletely abolished toxicity, fully validat-
ing a role for acetylation of these lysines in the alteredmetabolism and
toxicity of themutantAR in cellmodels of SBMA.
Although our studies reveal that deacetylation of K630/632/
633 by SIRT1 is the mechanism by which SIRT1 protects motor
neurons from polyQ-expanded AR toxicity, it is not completely
clear how the acetylation state of the mutant AR impacts its tox-
icity. In addressing this question, we discovered that acetylation
of K630/632/633 enhances the stabilization of polyQ-expanded
AR by DHT. As polyQ-expanded protein levels correlate with
aggregation and toxicity, even a modest disruption in mutant
protein turnover could substantially impact these components of
disease. However, modulating AR expression to levels similar to
those observed upon DHT binding of the acetylation-null AR
mutant fails to mimic the dramatic effect of this acetylation site
mutation on AR aggregation and toxicity (data not shown), sug-
gesting that additional factors are important in mediating the
effects of AR acetylation on its metabolism and toxicity.
Much is known about the function of AR acetylation. Acety-
lation of K630/632/633 stimulates the expression of AR target
genes by enhancing binding to coactivators, including p300/CBP,
whereas unacetylated AR recruits AR corepressors such as N-Cor
(Fu et al., 2000, 2004).Whether components of the AR transcrip-
tional machinery modulate AR metabolism and toxicity in re-
sponse to its acetylation state is under investigation. In addition,
a relationship exists between AR acetylation and its phosphor-
ylation, as acetylation-site mutants exhibit reduced total AR
phosphorylation (Fu et al., 2004), another posttranslational
modification of the AR that contributes to disease (Palazzolo et
al., 2007, 2009). Acetylation of the AR may also impact the
amino-carboxyl interaction, a feature essential for mutant AR
aggregation and toxicity (Orr et al., 2010). In addition, the acet-
ylation status of the AR is known to alter the activation of specific
target genes (Fu et al., 2003) and to affect MEKK1-dependent
apoptosis (Fu et al., 2002). Thus, it may be that altered transcrip-
tional activation by the ARmutants used here contributed to the
distinct cellular phenotypes of survival and death.
In addition to achieving a better mechanistic understanding
of the role of polyQ-expanded AR acetylation in SBMA, it is
important to determine the basis of polyQ-expanded AR hyper-
acetylation. PolyQ-expanded AR was aberrantly acetylated in the
absence of hormone in a cell model of SBMA (Lieberman et al.,
2002). In our current studies, in the presence of DHT, polyQ-
expansion was associated with AR hyperacetylation. The cause of
this enhanced acetylation is currently unclear. Hyperacetylation
of the mutant AR may result from the increased addition or the
Figure 11. Acetylation site mutation alters the stabilization of AR by DHT. PC12 cells ex-
pressing polyQ-expanded AR110Q with an exogenous nuclear localization signal in triplicate
(NLSX3) at the N terminus were used for these studies. Cells expressing lysine-intact AR (AR-
110Q), AR with a single acetylation-null mutation (AR-K630A–110Q), a triple acetylation-null
mutant AR (AR-R3–110Q), or triple acetylation-mimic AR mutants (AR-T3–110Q or AR-Q3–
110Q)were treatedwith doxycycline (DOX) to express equivalent levels of AR for 48 h, thenDHT
samples were treated for an additional 36 h with 10 nM DHT in the absence of DOX. Western
analysis of AR (AR-H280) reveals reducedDHT-stabilization of acetylation-nullmutant AR110Q.
Statistical analysis was performed to determine differences between samples with or without
DHT for each cell line. Additionally, the percentage increase in AR levels in the presence of DHT
was compared between cell lines. Note that the T3 (acetylation-mimic) AR110Q AR is stabilized
substantially more than lysine-intact (K3) AR110Q. Student’s t test was used to determine
statistical significance.
17434 • J. Neurosci., November 30, 2011 • 31(48):17425–17436 Montie et al. • SIRT1 and AR Acetylation in SBMA
decreased removal of acetyl groups. The increased addition of
acetyl groups to the ARmay result from an increased association
of polyQ-expanded AR with histone acetyltransferases. For in-
stance, CBP, an acetyltransferase of the AR (Fu et al., 2000), is
sequestered into mutant AR nuclear inclusions (McCampbell et
al., 2000); perhaps an enhanced colocalization of CBP with mis-
folded polyQ-expandedAR increases the transfer of acetyl groups
to the AR. Alternatively, theremay be decreased removal of acetyl
groups from polyQ-expanded AR, resulting from reduced inter-
action of mutant AR with a deacetylase. Our finding that in-
creased expression of the AR deacetylase SIRT1 reduced the
acetylation of polyQ-expanded AR indicates that the mutant AR
is capable of being deacetylated. Finally, polyQ-expanded AR
hyperacetylation may represent an un-degraded species of the
protein, consistent with our studies revealing enhanced DHT-
stabilization of acetylated AR.
Acetylation affects other polyQ-expanded proteins through
disparate roles in pathogenesis. Acetylation of lysine 444 of the
huntingtin protein enhances its turnover by the autophagic path-
way, highlighting acetylation of huntingtin as a protective mod-
ification (Jeong et al., 2009). However, in models of SCA-7, the
acetylation of polyQ-expanded ataxin-7 decreases its turnover,
leading to accumulation of a toxic fragment of polyQ-expanded
ataxin-7 (Mookerjee et al., 2009). Our studies indicate that one
mechanism bywhich acetylation of polyQ-expandedAR alters its
metabolism and toxicity is through its impact on protein turn-
over. Thus, it appears that the differential roles of acetylation,
with regard to the metabolism of the mutant protein and its
neuronal toxicity, depend upon the protein within which the
polyQ expansion is contained. This highlights the significance of
protein context and the importance of understanding the normal
metabolism and function of polyQ-expanded proteins when in-
vestigating mechanisms of disease.
In addition to direct effects on polyQ proteins, acetylation can
have indirect effects on polyQ protein toxicity. For example, in-
creasing CBP/p300 levels in a Drosophilamodel of polyQ disease
reduced aggregation of a polyQ peptide (Taylor et al., 2003),
while in our studies, inhibition of CBP/p300 with anacardic acid
reduced polyQ expanded AR aggregation. It may be that the
pathogenic pathways in these models differ, due to either differ-
ences in the polyQ proteins themselves or to the in vivo versus in
vitro settings. Our studies of AR acetylation in mouse models of
SBMA should clarify this discrepancy.
We have demonstrated that the ability of SIRT1 to deacetylate
polyQ-expanded AR is central to its neuroprotection in cell cul-
ture models of SBMA. The finding that SIRT1 failed to protect
motor neurons from DHT-dependent toxicity of a polyQ-
expanded AR that was refractory to SIRT1 deacetylation was some-
what surprising, given the effect of SIRT1on several neuroprotective
pathways in models of other neurodegenerative diseases. Whether
the ability of SIRT1 to protect from polyQ-expanded AR toxicity in
vivo is similarly dependent on its ability to deacetylate the AR is
under investigation. Nonetheless, the discovery of the mechanistic
basis for the neuroprotection by SIRT1 in SBMA motor neurons
highlights both the vital role of AR acetylation in disease and the
therapeutic potential of targeting both SIRT1 and AR acetylation in
SBMA.
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